Phase 3 Lung Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are able and willing to sign a consent form and follow all study requirements and procedures.
- People aged 18 to 75 years old at the time of joining the trial.
- People with a general health and activity level rated as fully active or restricted only in physically strenuous activity (confirm with trial site).
- People with a life expectancy of at least 3 months.
- People who have a confirmed diagnosis of non-small cell lung cancer (NSCLC), confirmed through tissue or cell testing.
- People whose NSCLC is locally advanced or has spread to other parts of the body.
- People who have previously been treated with platinum-based chemotherapy and a type of immunotherapy called a PD-1/PD-L1 inhibitor.
- People who have at least one tumour that can be measured on scans, according to standard criteria.
- People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer has been found to include a type called small cell lung carcinoma.
- People who have had another cancer within the 3 years before joining the trial.
- People who have specific known genetic changes in their cancer that could be targeted by other treatments (confirm with trial site).
- People who have previously received immunotherapy other than PD-1/PD-L1 inhibitors.
- People who have previously been treated with a chemotherapy drug called docetaxel.
- People with a history of serious bleeding problems or issues with blood clotting.
- People who have had an autoimmune disease requiring ongoing medication within the 2 years before joining the trial.
- People with a history of heart muscle inflammation, heart muscle disease, or serious irregular heart rhythms.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Caicun Zhou, Shanghai East Hospital
Phone: 18116403289
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.